November 18, 2019 Ninfetanib Improves and Stabilizes Lung Function in Systemic Sclerosis Patients who have systemic sclerosis-associated interstitial lung disease and received nintedanib were more likely to have improved lung function than patients who received a placebo, according to a new study. Not only did nintedanib improve forced vital capacity, but patients who received the drug were less likely to experience declining clinical status and more likely to see their conditions stabilize. Learn more   New Etiology of Rheumatoid Arthritis Identified in the Gut Microbiome Scientists now have a better understanding of the relationship between the gut microbiome and rheumatoid arthritis. Learn more   ACR Annual Meeting Roundup: Higher death rates in lupus In today's slideshow, we highlight the best of the ACR Annual Meeting which wrapped this week in Atlanta. Among the highlights, includes a study that focuses on unusually high death rates in lupus, plus one that suggests new treatments for juvenile idiopathic arthritis are "urgently" needed. Learn more in this slideshow.